37 related articles for article (PubMed ID: 16485120)
1. Effects of solvents on in vitro potencies of platinum compounds.
Yi YW; Bae I
DNA Repair (Amst); 2011 Nov; 10(11):1084-5. PubMed ID: 21978437
[No Abstract] [Full Text] [Related]
2. Treatment of clinical stage I non-seminoma.
Winter C; Hiester A
Asian J Urol; 2021 Apr; 8(2):161-169. PubMed ID: 33996471
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Novel Acetylcholinesterase Inhibitor by Fragment-Based Design and Virtual Screening.
Stavrakov G; Philipova I; Lukarski A; Atanasova M; Georgiev B; Atanasova T; Konstantinov S; Doytchinova I
Molecules; 2021 Apr; 26(7):. PubMed ID: 33916760
[TBL] [Abstract][Full Text] [Related]
4. Tumor suppressor miR‑613 induces cisplatin sensitivity in non‑small cell lung cancer cells by targeting GJA1.
Luo J; Jin Y; Li M; Dong L
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760215
[TBL] [Abstract][Full Text] [Related]
5. Galantamine-Curcumin Hybrids as Dual-Site Binding Acetylcholinesterase Inhibitors.
Stavrakov G; Philipova I; Lukarski A; Atanasova M; Zheleva D; Zhivkova ZD; Ivanov S; Atanasova T; Konstantinov S; Doytchinova I
Molecules; 2020 Jul; 25(15):. PubMed ID: 32717861
[TBL] [Abstract][Full Text] [Related]
6. Iridium (III) complex-loaded liposomes as a drug delivery system for lung cancer through mitochondrial dysfunction.
Liao C; Xu D; Liu X; Fang Y; Yi J; Li X; Guo B
Int J Nanomedicine; 2018; 13():4417-4431. PubMed ID: 30104875
[TBL] [Abstract][Full Text] [Related]
7. Novel hits for acetylcholinesterase inhibition derived by docking-based screening on ZINC database.
Doytchinova I; Atanasova M; Valkova I; Stavrakov G; Philipova I; Zhivkova Z; Zheleva-Dimitrova D; Konstantinov S; Dimitrov I
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):768-776. PubMed ID: 29651876
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological effects of asiatic acid in glioblastoma cells under hypoxia.
Thakor FK; Wan KW; Welsby PJ; Welsby G
Mol Cell Biochem; 2017 Jun; 430(1-2):179-190. PubMed ID: 28205096
[TBL] [Abstract][Full Text] [Related]
9. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization.
Fischer C; Leithner K; Wohlkoenig C; Quehenberger F; Bertsch A; Olschewski A; Olschewski H; Hrzenjak A
Mol Cancer; 2015 Jan; 14():4. PubMed ID: 25608569
[TBL] [Abstract][Full Text] [Related]
10. Urinary parameters predictive and electrolyte disturbances of cisplatin-induced acute renal associated with cancer as a critical target of the chemotherapeutic agent in patients with solid tumors.
Pedram B; Moghadam AT; Kamyabi-Moghaddam Z; Mavedati O; Beigi BA; Sharabiyani AK; Dezfuli AB; Khalili S; Bahrami AM; Nasoori A
Tumour Biol; 2015 Jun; 36(6):4495-500. PubMed ID: 25596088
[TBL] [Abstract][Full Text] [Related]
11. Impact of inhomogeneous static magnetic field (31.7-232.0 mT) exposure on human neuroblastoma SH-SY5Y cells during cisplatin administration.
Vergallo C; Ahmadi M; Mobasheri H; Dini L
PLoS One; 2014; 9(11):e113530. PubMed ID: 25423171
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects.
Florea AM; Büsselberg D
Cancers (Basel); 2011 Mar; 3(1):1351-71. PubMed ID: 24212665
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
14. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
15. Comparative assessment of the cytotoxic effects of carboxylato-bridged dinuclear platinum (II) complexes against human tumor cell lines.
Momekov G; Bakalova A; Konstantinov S; Todorov D; Karaivanova M
Neoplasma; 2005; 52(6):469-75. PubMed ID: 16284691
[TBL] [Abstract][Full Text] [Related]
16. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
Ali BH; Al Moundhri MS
Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
[TBL] [Abstract][Full Text] [Related]
17. Neurotoxicity Associated with Platinum-Based Anti-Cancer Agents: What are the Implications of Copper Transporters?
Stojanovska V; McQuade R; Rybalka E; Nurgali K
Curr Med Chem; 2017; 24(15):1520-1536. PubMed ID: 28079002
[TBL] [Abstract][Full Text] [Related]
18. In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands.
Momekov G; Ferdinandov D; Bakalova A; Zaharieva M; Konstantinov S; Karaivanova M
Arch Toxicol; 2006 Sep; 80(9):555-60. PubMed ID: 16485120
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
